Get the Stockscreener App
8.71
3.44%
-0.31
Organon Co stock is traded at $8.71, with a volume of 3.91M.
It is down -3.44% in the last 24 hours and down -31.09% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$9.02
Open:
$9.1
24h Volume:
3.91M
Relative Volume:
0.80
Market Cap:
$2.49B
Revenue:
$6.41B
Net Income/Loss:
$1.30B
P/E Ratio:
1.7282
EPS:
5.04
Net Cash Flow:
$646.00M
1W Performance:
-9.18%
1M Performance:
-31.09%
6M Performance:
-45.70%
1Y Performance:
-57.53%
1-Day Range:
$8.71
$9.13
1-Week Range:
$8.05
$9.41
52-Week Range:
$8.05
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
8.71 | 2.49B | 6.41B | 1.30B | 646.00M | 5.04 |
|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
OGN STOCK ALERT: Levi & Korsinsky Notifies Organon & Co. Investors of an Ongoing Investigation - ACCESS Newswire
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORGANON ALERT: Bragar Eagel & Squire, P.C. is Investigating Organon & Co. on Behalf of Organon Stockholders and Encourages Investors to Contact the Firm - TradingView
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge - simplywall.st
Levi & Korsinsky Announces an Investigation on Behalf of Organon & Co. (OGN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
EMA Confirms Suicidal Ideation As A Side Effect Of Finasteride 1 And 5 Mg Tablets - marketscreener.com
Organon: Management Slashes DividendThis Feels Disastrous (NYSE:OGN) - Seeking Alpha
2025-05-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Stockholders to Learn More About the Investigation | NYSE:OGN | Press Release - Stockhouse
Ex-Dividend Reminder: H2O America, Exelon Corp and Organon & Co - Nasdaq
EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drug - marketscreener.com
Organon Executives Make Bold Moves with Major Stock Purchases - TipRanks
Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment - simplywall.st
Insider Buying: Aaron Falcione Acquires Shares of Organon & Co (OGN) - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Organon & Co. (OGN) - ACCESS Newswire
Organon & Co. Executives Increase Their Holdings - TradingView
Income Investors Should Know That Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon - simplywall.st
Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon - Yahoo Finance
FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN
Levi & Korsinsky Reminds Organon & Co. Investors of the Ongoing Investigation into Potential Violations of Securities LawsOGN - ACCESS Newswire
Top Executives Make Bold Moves with Major Organon Stock Purchases! - TipRanks
Organon & Co. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsOGN - PR Newswire
Did Organon & Co. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateOGN - ACCESS Newswire
Organon downgraded to In Line from Outperform at Evercore ISI - MSN
Organon & Co. Executives Make Significant Stock Purchases - TradingView
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Organon (OGN) Faces Price Target Cut Amid Dividend Adjustment - GuruFocus
OGN Stock: Analyst Maintains Rating, Lowers Price Target to $10 | OGN Stock News - GuruFocus
Organon price target lowered to $10 from $15 at Morgan Stanley - TipRanks
OGN INVESTIGATION ALERT: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm - PR Newswire
Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02 - simplywall.st
Organon & Co. (NYSE:OGN) Q1 2025 Earnings Call Transcript - Insider Monkey
SLQT INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into SelectQuote, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - GlobeNewswire Inc.
OGN INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Organon price target lowered to $10 from $11 at BofA - Yahoo Finance
Organon projects over $1B in Nexplanon revenue for 2025 amid continued expansion - MSN
Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon (OGN) - Seeking Alpha
Organon & Co. SEC 10-Q Report - TradingView
Evercore ISI Downgrades Organon to In Line From Outperform - marketscreener.com
Organon Stock Tumbles To Record Low On Downgrades And Dividend Cut: Retail Optimism Persists - MSN
Organon & Co. Earnings Call: Growth Amid Challenges - TipRanks
Organon (OGN) Faces Downgrade Following Dividend Reduction | OGN Stock News - GuruFocus
Organon Co earnings beat by $0.11, revenue fell short of estimates - Investing.com Australia
Organon (OGN) Faces Price Target Reduction and Dividend Cut | OG - GuruFocus
OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm - Business Wire
Organon (OGN) Significantly Reduces Quarterly Dividend | OGN Sto - GuruFocus
Organon (OGN) Significantly Reduces Quarterly Dividend | OGN Stock News - GuruFocus
Organon (OGN) Sees Growth in Nexplanon and Strategic Restructuri - GuruFocus
Organon slashes dividend - CNBC
Organon (OGN) Expands Board with New Appointment - GuruFocus
Organon (OGN) Set to Announce Q1 2025 Financial Results - GuruFocus
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):